CNS recurrence of primary mediastinal large b-cell lymphoma after complete remission
- 158 Downloads
Primary mediastinal large B-cell lymphoma (PMBCL) has been firstly described by Levitt et al. in 1982 and, by definition, it consists of an intrathoracic lymphoma without demonstrable evidence of extrathoracic disease, after careful clinical staging . It is a distinct clinical and pathological entity, and it is thought to arise from thymic medullary B cells. It typically affects young women, during their third or fourth decade of life, and it presents with rather homogeneous clinical aspects related to rapidly growing mediastinal masses, such as cough, dyspnoea, chest pain; in a minority of cases, superior vena cava syndrome, jugular vein distension and mantle oedema may also be reported [1, 2]. Although it is a local invasive neoplasm, extranodal and distant dissemination, as well as marrow infiltration, tend to be quite rare at presentation .
Central nervous system (CNS) relapse of PMBCL is a rather infrequent complication, consisting of a difficult therapeutic...
KeywordsCentral Nervous System Involvement Aggressive Lymphoma Central Nervous System Relapse Central Nervous System Prophylaxis Secondary Central Nervous System
- 1.Levitt LJ, Aisenberg AC, Harris NL et al (1982) Primary non-Hodgkin’s lymphoma of the mediastinum. Cancer 50:2486–2492. doi: 10.1002/1097-0142(19821201)50:11<2486::AID-CNCR2820501138>3.0.CO;2-G CrossRefPubMedGoogle Scholar
- 8.Haioun C, Besson C, Lepage E et al (2000) Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin’s lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Ann Oncol 11:685–690. doi: 10.1023/A:1008394827806 CrossRefPubMedGoogle Scholar
- 10.Boehme V, Zeynalova S, Kloess M et al (2007) Incidence and risk factors of central nervous system recurrence in aggressive lymphoma––a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin’s Lymphoma Study Group (DSHNHL). Ann Oncol 18:149–157. doi: 10.1093/annonc/mdl327 CrossRefPubMedGoogle Scholar
- 11.Lister A, Abrey LE, Sandlund JT (2002) Central nervous system lymphoma. Hematology (Am Soc Hematol Educ Program):283–296. doi: 10.1182/asheducation-2002.1.283
- 16.Zinzani PL, Martelli M, Poletti V et al (2008) Practice guidelines for the management of extranodal non-Hodgkin’s lymphomas of adult non-immunodeficient patients. Part I: primary lung and mediastinal lymphomas. A project of the Italian Society of Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 93:1364–1371. doi: 10.3324/haematol.12742 CrossRefPubMedGoogle Scholar
- 19.Barosi G, Carella A, Lazzarino M et al (2006) Management of nodal diffuse large B-cell lymphomas: practice guidelines from the Italian Society of Hematology, the Italian Society of Experimental Hematology and the Italian Group for Bone Marrow Transplantation. Haematologica 91:96–103PubMedGoogle Scholar
- 25.Watterson J, Toogood I, Nieder M et al (1994) Excessive spinal cord toxicity from intensive central nervous system-directed therapies. Cancer 74:3034–3041. doi: 10.1002/1097-0142(19941201)74:11<3034::AID-CNCR2820741122>3.0.CO;2-O CrossRefPubMedGoogle Scholar